CLINICAL TRIALS PROFILE FOR ALTEPLASE
✉ Email this page to a colleague
All Clinical Trials for alteplase
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00000468 ↗ | Myocardial Infarction Triage and Intervention Project (MITI) | Completed | National Heart, Lung, and Blood Institute (NHLBI) | Phase 3 | 1988-04-01 | To determine the practicality, benefit, and safety of paramedic administration of thrombolytic therapy for acute myocardial infarction. The feasibility of paramedics correctly identifying candidates for thrombolytic therapy following myocardial infarction was assessed in Phase I. In Phase II, pre-hospital thrombolytic therapy was compared with in-hospital thrombolytic therapy. |
NCT00000468 ↗ | Myocardial Infarction Triage and Intervention Project (MITI) | Completed | University of Washington | Phase 3 | 1988-04-01 | To determine the practicality, benefit, and safety of paramedic administration of thrombolytic therapy for acute myocardial infarction. The feasibility of paramedics correctly identifying candidates for thrombolytic therapy following myocardial infarction was assessed in Phase I. In Phase II, pre-hospital thrombolytic therapy was compared with in-hospital thrombolytic therapy. |
NCT00044057 ↗ | A Study to Evaluate the Effects of YM872 on Brain Function and Disability When Administered in Combination With Alteplase (Tissue Plasminogen Activator) | Completed | Astellas Pharma US, Inc. | Phase 2 | 2000-12-01 | The purpose of this study is to determine if YM872 in combination with t-PA can reduce disability and brain damage from stroke. YM872 or placebo will be given as a continuous intravenous (iv) infusion for 24 hours. It is important that the study medication, YM872 or placebo, is administered prior to the completion of the t-PA administration. The clinical effects of YM872 in addition to t-PA will be determined by assessing neurological function and disability scores at follow up visits through Day 90 of the study. |
NCT00044057 ↗ | A Study to Evaluate the Effects of YM872 on Brain Function and Disability When Administered in Combination With Alteplase (Tissue Plasminogen Activator) | Completed | Astellas Pharma Inc | Phase 2 | 2000-12-01 | The purpose of this study is to determine if YM872 in combination with t-PA can reduce disability and brain damage from stroke. YM872 or placebo will be given as a continuous intravenous (iv) infusion for 24 hours. It is important that the study medication, YM872 or placebo, is administered prior to the completion of the t-PA administration. The clinical effects of YM872 in addition to t-PA will be determined by assessing neurological function and disability scores at follow up visits through Day 90 of the study. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for alteplase
Condition Name
Clinical Trial Locations for alteplase
Trials by Country
Clinical Trial Progress for alteplase
Clinical Trial Phase
Clinical Trial Sponsors for alteplase
Sponsor Name